webinar-presenations-download

May 12th, 2014, 16.00-17.00 CET (15:00 UK, 10:00 EST)

The EMA’s announcement of a pilot project in adaptive pathways, the UK government’s Early Access to Medicines Scheme (EAMS) and the FDA’s highly-publicised Breakthrough programme demonstrate an increase in international competition for a better, faster, approval plan for the development of needed new medicines.

 

 

Featuring:

 richard-barker  James-sq  Nathalie_small-sq
Richard Barker,
Director,
CASMI
James Anderson,
Director of EU Industry & External Partnerships,
GSK
Nathalie Seigneuret,
Senior Scientific Project Manager,
Innovative Medicines Initiative (IMI)
 john-parkinson  samantha-roberts-bio-sq
John Parkinson,
Director of the Clinical Practice Research Datalink,
MHRA
Samantha Roberts,
Head of Science Policy,
Friends of Cancer Research

The webinar supported by:

casmi

efpia

For more information:

Comparison of EU and USA licensing flexibilities (click to download the full table)

image-table1

 

Comparison of Breakthrough therapy designation and MHRA processes (click to download to download the full table)

image-table2

Read the full report from MHRA: Report of the Expert Group on innovation in the regulation of healthcare – 25 September 2013